TP53 and leukemia: RG7388 was the first MDM2–p53-binding antagonist to progress through phase II clinical studies (ClinicalTrials.gov Identifier: NCT02633059), and according to preliminary clinical trial outcomes, shows encouraging potential for inclusion as a therapeutic drug for wild-type p53 leukemia [3].